Clinical Trial Update: Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Sibeprenlimab for immunoglobulin A nephropathy is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• Sibeprenlimab

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: IgA Nephropathy | Phase 2 | Status: RECRUITING